Condition
Idiopathic Retroperitoneal Fibrosis
Total Trials
6
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
67%
4 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 3 (1)
P 4 (3)
Trial Status
Unknown3
Recruiting3
Clinical Trials (6)
Showing 6 of 6 trials
NCT05428826Phase 4RecruitingPrimary
Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis
NCT04762784Phase 4UnknownPrimary
A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis
NCT04762810Phase 4UnknownPrimary
A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis
NCT04314323RecruitingPrimary
National Registry of IRPF in China
NCT04312854RecruitingPrimary
A Prospective Cohort Study of IRPF in China
NCT01240850Phase 3UnknownPrimary
Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial
Showing all 6 trials